Study Assesses Epidemiology of Carbapenem-resistant Enterobacteriaceae

Share this content:

the ONA take:

Most carbapenem-resistant enterobacteriacecae (CRE) cases in the United States are associated with a high prevalence of prior hospitalizations or indwelling devices and discharge to long-term care settings, a study published in JAMA has shown.

Because CRE cases have been increasingly reported worldwide as a cause of infection with high-mortality rates, researchers sought to determine the population-based CRE incidence in seven US geographical areas.

For the study, researchers analyzed case records from persons living in 1 of 7 US metropolitan areas in Colorado, Georgia, Maryland, Minnesota, New Mexico, New York, and Oregon.

Results showed that the incidence of CRE was 2.93 per 100,000 people. Researchers also found that the majority of CRE cases were in women.

CRE cases were significantly higher than predicted for Georgia, Maryland, and New York, while Colorado, New Mexico, and Oregon had significantly fewer cases than predicted.

The study demonstrated that most CRE cases occurred in patients with prior hospitalizations or indwelling devices, and the majority of admitted cases results in discharge to a long-term care setting.

The carbapenem antibiotic class includes imipenem, meropenem, doripenem, and ertapenem. Extended-spectrum cephalosporin-resistant enterobacteriaceae are typically susceptible to carbapenems except ertapenem.

Recreational use of this fast-acting drug can be fatal
Most carbapenem-resistant enterobacteriacecae (CRE) cases associated with a high prevalence of prior hospitalizations.
Importance Carbapenem-resistant Enterobacteriaceae (CRE) are increasingly reported worldwide as a cause of infections with high-mortality rates. Assessment of the US epidemiology of CRE is needed to inform national prevention efforts. Objective To determine the population-based CRE incidence and describe the characteristics and resistance mechanism associated with isolates from 7 US geographical areas.
READ FULL ARTICLE From Jamanetwork
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs